France's Centre National De Genotypage Purchases Production-Scale SNP Genotyping BeadLab from Illumina.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2004 Illumina's BeadArray(TM) Technology to Enable Expanded Scale of Research for Identifying Genes Associated with Hereditary Diseases Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Centre National de Genotypage (CNG CNG Compressed Natural Gas CNG Calling (Tone) CNG Comfort Noise Generation CNG Cryptography Next Generation (Microsoft Windows Vista) CNG Centre National de Génotypage ), located in Evry, France, for the purchase of an Illumina(R) BeadLab. The BeadLab, a production-scale SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily (single nucleotide polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a ) genotyping laboratory, will constitute an integral component of the Centre's state-of-the-art capabilities devoted to understanding the functional implications of sequence variation in the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. and other model organisms. The BeadLab will be installed at CNG's Evry research campus near Paris and used to conduct large-scale genotyping projects in collaboration with research groups at the national, European, or international level covering a variety of inherited diseases including diabetes and hypertension. These large projects will help researchers understand the role of genetic variation in disease susceptibility and facilitate the identification of genes associated with inherited diseases. The BeadLab is an end-to-end genotyping solution built around Illumina's proprietary BeadArray(TM) technology and featuring high sample throughput, low running cost per SNP scored and industry-leading performance. When installed, the genotyping laboratory at CNG will have the capacity to produce routinely over eight hundred thousand genotypes per day. "CNG is a world leader in genetic research and we look forward to developing a strong, collaborative relationship," stated Jay Flatley, Illumina President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Our genotyping BeadLab will expand significantly the potential scale of genomics research conducted at CNG and help the Centre's investigators and colleagues better understand the complex relationships between genetics and disease." CNG is a part of the CNRG CNRG Computer Network Research Group (University of Massachusetts, Amherst; Institute of Technology, Bandung, Indonesia) (Consortium National de Recherche re·cher·ché adj. 1. Uncommon; rare. 2. Exquisite; choice. 3. Overrefined; forced. 4. Pretentious; overblown. en Genomique). In addition to CNG, CNRG members include CNS See Continuous net settlement. CNS See continuous net settlement (CNS). (Centre National de Sequencage) and the Genopole(R). Additional information about the Centre National de Genotypage can be found at http://www.cng.fr. Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements are Illumina's ability to continue to improve its BeadArray and Oligator technologies, the Company's ability to reproducibly manufacture Array Matrices and BeadChips and to reconfigure these platforms to other geometries, the Company's ability to successfully build out international sales and support organizations, the Company's ability to develop and deploy new applications for its platform technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion